VEGFA and cancer: Bevacizumab, the first vascular endothelial growth factor (VEGF)-targeting drug officially approved for cancer therapy is a humanized monoclonal antibody IgG1 that blocks the binding of human VEGF to its receptors, thus disrupting autocrine and paracrine survival mechanisms mediated by VEGF-1 and VEGF-2 19.